GE HealthCare Technologies Inc. (GE HealthCare) is a leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics.
The company operates at the center of the healthcare ecosystem, enabling precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater effi...
GE HealthCare Technologies Inc. (GE HealthCare) is a leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics.
The company operates at the center of the healthcare ecosystem, enabling precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. The company’s products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from screening and diagnosis to therapy and monitoring.
The pursuit of precision care opportunities significantly expands the company’s addressable markets to include integrated diagnostics, artificial intelligence (AI), and machine learning-based clinical decision support, highly personalized therapies enabled by more precise diagnostics, and remote patient monitoring. The scale and breadth of the company’s portfolio, combined with its innovation capabilities, position it to be a leading enabler of precision care.
The company generates revenue from the sale of medical devices, consumable products, service capabilities, and digital solutions. The company serves customers in over 160 countries with a global team of approximately 9,800 sales professionals and 8,300 field service engineers. The company’s customers are healthcare providers and researchers, including public, private, and academic institutions.
The company develops, manufactures, and markets a broad portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. The company has a large, global installed base of medical imaging, ultrasound, and patient monitoring systems.
Segments
The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
Imaging
GE HealthCare is a global leader in medical imaging with a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. The company’s Imaging portfolio spans the care continuum and provides critical tools for clinicians, from initial screening and diagnosis, through therapeutic decision-making and monitoring of patient progression. The company’s products support providers in the delivery of care for a broad spectrum of clinical specialties, including oncology, cardiology, neurology, nuclear medicine, orthopedics, women’s health, pediatrics, and surgery.
The company’s Imaging portfolio consists of five product lines and associated service capabilities: Molecular Imaging, Computed Tomography, Magnetic Resonance, Women’s Health, and X-ray. The company manages its Molecular Imaging and Computed Tomography product lines together (MI/CT) and its Women’s Health and X-ray product lines together (WH/XR).
Molecular imaging (MI) enables the visualization, characterization, and quantification of functional processes taking place at the cellular and subcellular levels within patients. The images produced by MI systems allow clinicians to study the cellular and molecular pathways and mechanisms of disease in patients. The company offers a complete MI solution from cyclotrons, chemistry synthesis, positron emission tomography (PET), computed tomography (PET/CT), PET/MR, and nuclear medicine to advanced digital and AI-enabled solutions. The company’s Molecular Imaging team works closely with the PDx segment and their innovations and collaborations with pharmaceutical companies.
Computed tomography (CT) scans render 3D anatomical images of structures, such as bone, soft tissue, and air cavities using an X-ray tube that rotates around a patient. The images are used in a wide variety of applications, including the detection of tumors or lesions, blocked blood vessels in the brain, abnormal heart conditions, complex bone fractures, and internal injuries from trauma. The company’s comprehensive Computed Tomography portfolio includes multi-purpose and specialty scanners.
Magnetic resonance (MR) is a non-invasive imaging technology that produces detailed anatomical images of almost every internal structure in the human body, such as the brain, spinal cord, heart, breast, kidneys, muscles, ligaments, and tendons. MR can also be used for functional imaging, and it is well-suited for disease detection, diagnosis, and treatment monitoring of a variety of conditions, including stroke, cancer, trauma, aneurysm, multiple sclerosis, cardiomyopathy, and congenital disorders. The company’s Magnetic Resonance portfolio includes scanners for a range of clinical capabilities through different bore sizes, magnetic field strengths, and scalable platforms.
Women’s Health products use X-ray technology to help clinicians screen for and diagnose breast cancer, as well as bone and metabolic diseases in women. The product portfolio includes imaging and biopsy positioning systems designed to image the breast and dual energy X-ray absorptiometry scanners designed to image bones with low mineral density.
X-ray systems are used by clinicians to perform first-line diagnostic imaging examinations of anatomical structures in the body, such as bones, lungs, and the gastrointestinal tract. The company’s X-ray product portfolio includes systems for three distinct clinical situations: fixed room radiography products installed in hospitals and imaging centers; mobile radiography products used for bedside or other point-of-care imaging needs; and fluoroscopy products installed in hospitals for dynamic or moving X-ray imaging in applications like gastrointestinal examinations.
The company also offers a suite of AI-enabled software and applications that help clinicians improve productivity, address staff shortages, and deliver better patient outcomes. These software solutions and applications are upgradable through the lifecycle of the equipment and are especially beneficial for multi-site, multi-disciplinary networks that have complex operations. The company also offers Picture Archiving and Communication Systems (PACS) and Radiological Information Systems to manage the storage and reporting of radiology images.
In addition to its core products, digital solutions, and service offerings, the company provides complementary enterprise solutions, such as education and training and data integration services. The company’s broad enterprise solutions used along the imaging continuum enable it to drive connectivity across healthcare systems and throughout the product lifecycle.
Advanced Visualization Solutions
GE HealthCare is a global leader in ultrasound, image guided therapies, and interventional solutions with a broad portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The company’s AVS business focuses on designing solutions that are aligned by specialties or care areas for specific clinical workflows to better serve the unique needs of its customers and improve patient outcomes. The company continues to deliver innovative solutions to support interventional procedures, all with digital and AI-enabled solutions that help clinicians increase diagnostic confidence, while simplifying clinical and operational workflows.
The AVS segment has a portfolio that serves customers across two core areas: Specialized Ultrasound and Procedural Guidance. Specialized Ultrasound includes Comprehensive Care Ultrasound, and Women’s Health Ultrasound. Procedural Guidance includes CardioVascular and Interventional Solutions, and Surgical Innovations.
Comprehensive Care Ultrasound includes systems that produce images to support precise screening, diagnosis, monitoring, and treatment across the whole body, including liver, thyroid, kidney, breast, vascular, and transcranial applications. These systems include point of care and handheld ultrasound devices to support clinical decision-making throughout various care pathways in diverse sites of care. The company’s systems combine high image quality with comprehensive clinical tools, including measurement quantification, workflow automation, cross-modality networking, real-time and AI-enabled scan guidance, and cloud-based technologies with versatility, accessibility, and portability required to deliver care.
Women’s Health Ultrasound provides systems to support obstetrics, gynecology, and assisted reproductive medicine. These care areas require specially designed ultrasound products that account for patient comfort and workflow constraints to enable practitioners to provide higher-quality screening, exams, and procedural care, and give clinicians images with the clarity and definition they need to focus on early detection and intervention.
CardioVascular and Interventional Solutions provides clinicians with tools to diagnose, treat, and monitor cardiovascular conditions with precision and confidence as well as technologies to help assist clinicians and surgeons during open surgeries and minimally invasive and interventional procedures. This includes ultrasound systems used to assess the structure and function of the heart, as well as real-time advanced X-ray imaging that integrates with ultrasound and other imaging and diagnostic systems. These technologies support planning, guiding, and assessing a variety of surgical procedures like cardiac interventions and those that involve insertion of devices like deep brain stimulators, spinal implants, and other neurological devices.
Surgical Innovations products are used in the operating environment and include a broad portfolio of advanced mobile surgical C-arms that meet clinical needs for surgical imaging and are designed to be easily maneuverable in crowded operating rooms and adaptable for various surgical procedures. Surgical visualization and guidance technology expands the use of ultrasound beyond diagnostics to provide real-time information during surgical procedures to help guide interventions and navigate inside the human body.
Each clinical area is supported with the company’s digital and AI-enabled ultrasound solutions that are designed to deliver optimal, simplified, and scalable clinical and operational workflows. They are designed to increase efficiencies that support care for more patients by providing AI-guided ultrasound to help clinicians of all experience levels acquire quality diagnostic images; eliminating keystrokes to shorten exam time; and providing clinical decision support tools. Clinicians are further supported by the company’s broad probe portfolio which includes specialized probes for interventional procedures. The company’s equipment, digital, and AI solutions are complemented by service offerings that are highly regionalized according to local requirements, varying customer needs, and cross-modality service strategies.
Patient Care Solutions
GE HealthCare’s PCS segment is a leading global provider of medical devices, proprietary parameters and consumables, services, and digital solutions that acquire and transform complex clinical data into real-time visualization and clinical decision support to ease the way to more confident patient care and improve patient outcomes. These solutions form a broad and integrated portfolio that support patient care needs and care teams within and beyond most acute healthcare environments.
The company’s PCS portfolio serves care teams and healthcare systems across multiple patient care needs, including Monitoring Solutions and Life Support Solutions. Monitoring Solutions includes Patient Monitoring, Diagnostic Cardiology, Consumables and Services portfolio, and Digital Solutions. Life Support Solutions includes Maternal Infant Care and Anesthesia.
The company’s flexible Patient Monitoring solutions enable clinicians to flex care based on a patient’s acuity and across the care continuum. The company’s portfolio ranges from spot-check to continuous patient monitoring, including comprehensive multi-parameter monitors; central stations; continuous, wearable, and mobile monitors; transport monitors; cardiac telemetry solutions; spot-check monitors; and visualization, alarm distribution, and care team collaboration solutions. The company’s Patient Monitoring business includes proprietary parameters and complementary consumables as well as original equipment manufacturers’ parameters that are integrated into its monitoring fleet, of which a significant portion represents recurring revenue streams.
In Diagnostic Cardiology, the company offers electrocardiogram (ECG or EKG) solutions, that are usually the first diagnostic tool to detect cardiovascular disease, a leading cause of death globally. The company provides resting ECG devices, stress ECG devices, and ECG management digital solutions, including interpretation algorithms. The company’s ECG ecosystem obtains, interprets, and stores ECGs captured from devices in both hospital and home settings, supporting patients and clinicians along the continuum of cardiology care.
The company’s Consumables and Services portfolio consists of approximately 1,000 consumables that are used throughout the hospital primarily with its monitors and therapy devices, such as blood pressure, ECG, pulse oximetry, temperature, respiratory rate, blood oxygen level, and brain activity. The company’s service offerings are flexible and can range from preventative maintenance to comprehensive, onsite biomedical service engineering contracts. Both the company’s consumables and services provide its customers with ongoing clinical impact and protect their capital investment while providing it with recurring revenue streams.
The Patient Care Solutions portfolio also includes digital solutions that provide clinical decision support in acute and other care settings, simplifying clinical and operational workflows to drive efficiencies and helping improve delivery of precision medicine and patient outcomes. These solutions aggregate and integrate clinical data from various devices across care settings in real time and simplify visualization to guide clinical and operational decisions, enabling more efficient care team collaboration, virtually. These solutions are interoperable and vendor-agnostic to integrate with customer environments in a multi-vendor setting and provide a recurring revenue stream.
The company’s Maternal Infant Care products are used in the labor and delivery department to monitor important maternal and fetal parameters, and in neonatal intensive care to assist in critical care for newborns. The company’s product portfolio includes neonatal incubators, infant warmers, resuscitation devices, phototherapy equipment, maternal and fetal monitors, and digital offerings, such as maternal and fetal heart rate surveillance software. The company’s products have added innovation in design, including integrated scales, hands-free alarm silencing, angled radiant heating, and thermoregulation.
Anesthesia products offer life support solutions via ventilation technology and are used by anesthesiologists and nurse anesthetists to ventilate and deliver general anesthetic drugs to patients during surgeries. The company’s products are installed in many operating rooms, non-operating room anesthesia environments, and ambulatory surgical centers across the world.
Pharmaceutical Diagnostics
GE HealthCare is a leading supplier of contrast and radiopharmaceutical imaging agents to the global radiology and nuclear medicine industries. These agents help clinicians assess patients to enable more precise diagnoses, monitor disease progression, and enable better therapy selection. The company distributes products globally that help meet patient and procedural needs across a multitude of modalities. PDx’s diagnostic agents are complementary to the imaging and ultrasound devices the company offers, including CT, angiography and X-ray, MR, single-photon emission computed tomography (SPECT) and PET, and are also compatible with systems from other equipment vendors.
PDx operates within a strictly regulated industry with unique operational needs. Diagnostic agents require a sophisticated supply chain for manufacturing, supported by a global infrastructure of commercial, marketing, medical affairs, market access, application, regulatory, and pharmacovigilance teams that help monitor products. Customers require timely and reliable supply of diagnostic agents as shortages or delays can be highly disruptive to workflows and even cause exam cancellations.
The company’s PDx business develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
Contrast media are pharmaceuticals that are administered to a patient prior to certain diagnostic scans in order to increase the visibility of tissues or structures during imaging exams. Contrast media increases the diagnostic value of imaging and can be critical in the visualization of small or nuanced areas of diagnostic interest, such as cancer lesions or vascular structures, and to plan medical interventions, such as angioplasties, biopsies, or radiation therapy. The company offers contrast media to three imaging modality groups: CT, angiography, and X-ray, MR, and Ultrasound. The company’s business also includes contrast injection devices that are automated devices used to monitor and control the injection of contrast into patients, providing valuable productivity benefits in the imaging suite. The company offers contrast injectors through collaborations with third-party original equipment manufacturers.
Radiopharmaceuticals, or molecular imaging agents, are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. These agents work by accumulating in an area of diagnostic interest, such as a tumor, and emitting energy that is detected by a SPECT or PET scanner. Because they have specific molecular targets, they allow visualization and assessment of cell function, providing a more detailed dimension of biological activity. The company’s radiopharmaceuticals support diagnosis and therapy selection in various care areas, such as neurology, cardiology, and oncology, and are also used by pharmaceutical companies and researchers in selecting target populations for clinical trials.
The company’s unique combination of imaging equipment and pharmaceutical diagnostics enables building capabilities across disease states through diagnostic pharmaceuticals, hardware, software, and AI and digital solutions. The company’s strong portfolio of diagnostic agents and advanced global supply chain, combined with its imaging, cyclotron, and advanced visualization software, positions it to grow in existing markets as well as emerging adjacencies.
Acquisitions
On December 1, 2024, the company announced an agreement to acquire the remaining stake in the Nihon Medi-Physics Co., Ltd (NMP) equity method investment to assume full ownership.
On April 1, 2024, the company acquired 100% of the stock of MIM Software Inc. (MIM Software)
On February 17, 2023, the company acquired 100% of the stock of Caption Health, Inc. (Caption Health)
Intellectual Property
As part of the Spin-Off from GE, the company secured IP specific to its business, and GE granted it a license to use other IP required for its business. The company also entered into a long-term trademark license agreement with GE that enables GE HealthCare to continue building upon its brand.
Competitors
The company’s primary global competitors include Siemens Healthineers, Philips Healthcare, Canon, Mindray, and United Imaging, among others. In its PDx business segment, the company primarily competes with Bayer, Bracco, Guerbet, and Curium.
Sales and Distribution Model
GE HealthCare deploys a global multi-channel commercial model consisting of approximately 9,800 sales professionals and a network of over 5,000 indirect third-party partners. The company’s reach into top hospitals and health systems is evidenced by its long-standing collaborations with leading institutions around the world. The company’s commercial model is organized according to the needs of its customers and includes global and regional marketing, regional inside sales teams, field-based sales teams, sales agents, and distributors. The company’s equipment sales representatives partner closely with their service sales counterparts to position both equipment contracts and long-term maintenance agreements along with system upgrades and software as a service (SaaS) agreement. The company complements its direct and indirect sales channels with end-to-end virtual sales teams. The company’s direct and indirect channel mix helps it expand its market coverage, increase customer satisfaction, and win more business in broad geographies and emerging markets. In developed markets, the company supplements its commercial model with strategic account executive and collaboration teams that bring the depth and breadth of its overall portfolio to the senior leadership of its top customers to deliver long-term commercial collaborations, which can be tied to specific outcomes.
Regulation
The U.S., European Union (EU), and China are the company’s most significant regions based on revenue and the regulatory landscape within these regions. The Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) (for pharmaceuticals) and European National Competent Authorities and Notified Bodies (for devices) in Europe, the National Medical Products Administration (NMPA) in China and other government agencies, such as state and local authorities, in the United States, Europe, and China, administer strict requirements governing the design, development, testing, performance, safety, quality, manufacturing, packaging, labeling, distribution, import/export, sale, servicing, marketing, and post-market surveillance of medical products, including medical devices and pharmaceutical products. In addition, the company is subject to applicable national and sub-national laws and regulations of other countries.
The company’s ability to market and sell its products globally depends upon its compliance with the laws and regulations in each jurisdiction in which the company develops, manufactures, or distributes its products. This requires, among other things, compliance with laws and regulations related to developing, testing, conducting clinical trials if needed, and receiving appropriate marketing authorization from the appropriate regulatory authorities prior to commercialization of the company’s products where necessary. The company is also subject to extensive laws and regulations requiring ongoing compliance and monitoring of its products throughout the product lifecycle. For example, the company has extensive processes and procedures for monitoring the post-market safety and performance of its products, reporting applicable events to regulators, and taking action to address potential safety or quality concerns where needed. In addition, regulators across the globe have the authority to conduct periodic inspections of the company’s facilities, products, and Quality Management System processes and procedures to evaluate its compliance with applicable laws and regulations. Regulators also monitor the company’s advertising and promotion of products for compliance with applicable laws and regulations.
Data Privacy Laws
Due to the company’s extensive global footprint and handling of personal data as both a data controller (on its own behalf) and data processor (on behalf of third parties, primarily customers), the company is also subject to an extensive collection of global laws and regulations protecting the privacy, security, and integrity of the personal data, sensitive personal data, and patient health information that it creates, receives, uses, and maintains as a business.
Among the most relevant and material to the company’s business, based on the volume and sensitivity of the data at issue, are: the U.S. Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information and Technology for Economic and Clinical Health Act (collectively HIPAA); the EU General Data Protection Regulation (Regulation (EU) 2016/679) (GDPR), similar U.K. legislation resulting from the European Union (Withdrawal) Data Act of 2018 (U.K. GDPR), and other EU country-level laws; the Lei Geral de Proteção de Dados Pessoias (Brazil LGPD); the various laws and accompanying regulations in China governing data privacy and cybersecurity (e.g., the Cybersecurity Law of the People’s Republic of China, Personal Information Protection Law (China PIPL) & Data Security Law (China DSL)), the Digital Personal Data Protection Act of India, and significant privacy legislation recently adopted in the Middle East and Africa Personal Data Protection Law (PDPL) Royal Decree No. M/19 on September 16, 2021. In addition, there are also various U.S. state-level laws (e.g., the California Consumer Privacy Act), country regional laws, and proposed legislation that the company monitors for applicability and impact to its business. These laws present a continuing challenge to businesses to structure their data collection, storage, use, and cross-border transmission in a compliant manner.
Global Healthcare Compliance
U.S. federal healthcare laws apply when the company or its customers submit claims for items or services that are reimbursed under Medicare, Medicaid, or other federally funded healthcare programs, including laws related to kickbacks, false claims, self-referrals, and healthcare fraud and abuse. Similar state false claims, anti-kickback, anti-self-referral, and insurance laws also apply to state-funded Medicaid and other healthcare programs and private third-party payers. Any failure to comply with these laws and regulations could subject the company or its officers and colleagues to criminal and civil financial penalties and expose the company to civil liability and risk of further enforcement action under the U.S. Anti-Kickback Statute (AKS), the False Claims Act (FCA), or other healthcare fraud and abuse laws. In addition, as a manufacturer of U.S. FDA-cleared and -approved devices and drugs reimbursable by federal healthcare programs, the company is subject to the U.S. federal Physician Payments Sunshine Act (the Sunshine Act), which requires the company to annually track and report to the federal government certain payments and other transfers of value it make to U.S.-licensed physicians and other healthcare professionals or U.S. teaching hospitals. Similar laws exist in some U.S. states as well.
History
The company was founded in 2022. The company was incorporated in 2022. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022.
